Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01382186 · ClinicalTrials.gov registry record

Veterans Experiences Using Secure Messaging

A clinical trial of Telemedicine, sponsored by US Department of Veterans Affairs.

Completed
Registry status
852
Enrollment target
2
Study locations

NCT01382186: Completed study of Telemedicine, sponsored by US Department of Veterans Affairs.

NCT01382186 is a study of Telemedicine that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 852 participants, below the 4,010-participant average among 18 other Telemedicine trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01382186, a study of Telemedicine, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
852 participants
Enrollment target
2
Study locations

Study Summary

Deployment of Secure Messaging (SM) in primary care and women's clinics throughout the Veteran Health System by 2011 was an implementation priority for the Secretary and Under Secretary for Health for FY11 under the VHA T21 initiative. Secure Messaging is in early phases of implementation, this eHealth tool requires thoughtful evaluation to promote the successful implementation and dissemination of this tool. The primary aim of this project is to describe Veterans' experiences when using the SM feature on MyHealtheVet (MHV). This project has local, VISN, and national impact on the implementation and sustainability of the SM feature on MHV through its qualitative and quantitative examination of users' experiences. Findings from this research explores why Veterans choose to, or not to, use the SM feature on MHV, identify facilitators and barriers, and examine if experiences differ by health literacy or computer literacy. In addition to the interview data, findings from the usability testing and the quantitative survey findings build knowledge about Veterans' experiences using the SM feature on MyHealtheVet. These data will inform systems improvements, educational approaches, and marketing strategies to increase adoption and long-term utilization among Veterans.

Primary Outcome

To determine ease of use and usefulness of secure messaging. Purposive sample of 33 participants were assessed for their ability to complete the following tasks: navigate to Secure Messaging, log-in to My HealtheVet and Secure Messaging, Set user preferences, check Secure Message inbox, open and send Secure Message, Open and read Secure Message attachment. Measured as: (1) able to complete task; (2) able to complete task with some difficulty; (3) not able to complete task.

Conditions Studied

Study Locations (2)

Florida

  • James A. Haley Veterans' Hospital, Tampa, FL - Tampa

Massachusetts

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston

Trial Details

FieldValue
Enrollment Target 852 participants
Start Date 2012-04
Est. Completion 2013-09
US Department of Veterans Affairs

632 total trials

What the finished NCT01382186 record still lists

NCT01382186 is an observational study that tracks outcomes without assigning an intervention. The registered 852 participants enrollment target is mid-sized for trials with a published cap, below the 4,010-participant average among 18 other Telemedicine trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Telemedicine appearing as the primary indexed condition, and to 0 interventions.

NCT01382186 reports a single indexed study location in Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01382186 about?

NCT01382186 is a clinical study titled "Veterans Experiences Using Secure Messaging". Deployment of Secure Messaging (SM) in primary care and women's clinics throughout the Veteran Health System by 2011 was an implementation priority for the Secretary and Under Secretary for Health for FY11 under the VHA T21 initiative. Secure Messaging is in early phases of implementation, this eHea...

What is the current status of trial NCT01382186?

This trial is currently completed. The enrollment target is 852 participants. The study started on 2012-04. Estimated completion is 2013-09.

What conditions does trial NCT01382186 study?

This clinical trial studies the following conditions: Telemedicine.

Who is sponsoring clinical trial NCT01382186?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01382186 being conducted?

This trial has 2 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Telemedicine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01382186's enrollment target sits among peer trials

852 9th of 18 higher than 10 of 18 other Telemedicine trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Telemedicine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06237452 · 852 participants · Phase 3

    VE303 for Prevention of Recurrent Clostridioides Difficile Infection

  • NCT06422143 · 851 participants · Phase 3

    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  • NCT07005102 · 854 participants · Phase 2

    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  • NCT07290491 · 854 participants · Phase 3

    Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01382186, the US trial registry maintained by the National Library of Medicine. NCT01382186 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.